Epidermal growth factor (EGF) is a recently described biomarker of acute GvHD (aGvHD). Whether low plasma EGF prior to hematopoietic cell transplantation (HCT) predisposes to the development of aGvHD, or whether EGF levels fall because of severe aGvHD, is unknown. To evaluate this, we tested plasma samples collected at pre-HCT baseline, day +28 and day +100 during the course of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402. We found that baseline EGF plasma concentrations were three-fold lower in HCT recipients compared to donors (24.3 vs 76.0 pg/mL, P o 0.01). Ninety-one patients (43%) had a markedly low plasma EGF at pre-HCT baseline, defined as o 2.7 pg/mL-an optimal cutpoint associated with development of grade III-IV aGvHD. Patients with these low EGF levels at pre-HCT baseline had a 2.9-fold increased risk of grade III-IV aGvHD by day +100. Patients with low EGF at day +28 after HCT had an increased risk of death (relative risk 2.3, P = 0.02) by 1 year due to transplant-related toxicities, especially aGvHD. Our results suggest that very low plasma EGF early in the HCT process may predispose patients to an increased risk of death, potentially due to epithelial damage and limited repair capacity.
INTRODUCTION
Epidermal growth factor (EGF) is a peptide growth factor central to restoration of epithelial and mucosal integrity after injury. [1] [2] [3] Receptors for EGF are located on keratinocytes in the basal layer of the epidermis 4 and basolateral surfaces of intestinal epithelial cells, particularly in crypts, 5 suggesting that EGF signaling may be critical for tissue repair after damage in these acute GvHD (aGvHD) target organs. We previously reported that circulating EGF plasma concentrations are two-to five-fold lower at the onset of aGvHD compared to hematopoietic cell transplant (HCT) recipients without aGvHD, with plasma EGF plasma concentrations declining to o10 pg/mL in steroid-refractory aGvHD. 6 However, it remains unknown whether low EGF plasma concentrations are a risk factor for, or a consequence of, aGvHD. It is also unknown whether EGF plasma concentrations in HCT recipients differ significantly from healthy donors. We compared recipient plasma EGF levels at pre-conditioning baseline, day +28, and day +100 after HCT with EGF levels in their healthy sibling donors collected during the course of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402 trial, 7 a prospective study of tacrolimus/sirolimus versus tacrolimus/methotrexate for aGvHD prophylaxis following myeloablative TBI-based conditioning, in order to probe this question.
PATIENTS AND METHODS
In this secondary analysis of BMT CTN 0402 longitudinal plasma samples, EGF plasma concentrations were determined using EGF-specific bead sets (MilliPLEX, Millipore, Billerica, MA, USA) with a lower limit of quantification (LLOQ) of 0.2 pg/mL. The missing data were not imputed, although EGF values that were oLLOQ were imputed as 0.2 pg/mL. EGF plasma concentrations across clinical variables (age, sex, year of HCT, aGvHD prophylaxis regimen, conditioning regimen, underlying disease, disease status at HCT and aGvHD grade) included recipients (N = 247 patients with samples available, although not every patient had a sample available at every time point) and donors (N = 117 with samples available). Comparisons of plasma concentrations were determined by the Wilcoxon rank sum test.
Because approximately half of HCT recipients in BMT CTN 0402 had EGF plasma concentrations oLLOQ (42% oLLOQ at baseline, 66% oLLOQ at day +28 and 52% o LLOQ at day +100), means, not medians, are reported throughout this analysis. In contrast to HCT recipients, only 13% of healthy donors had EGF plasma concentrations oLLOQ. Due to the large number of EGF values of LLOQ in HCT recipients, we defined an optimal cutpoint to determine the association between EGF and aGvHD. 8 The plasma concentration of EGF at pre-HCT baseline demonstrating the most significant difference in grade III-IV aGvHD incidence in this cohort was 2.7 pg/mL. Therefore, a plasma EGF concentration of o2.7 pg/mL is referred to as a low level of EGF throughout this report. Cox regression, using step-wise selection, was used to assess the independent effect of EGF levels at baseline, day +28 and day +100 on overall survival. 9 Likewise, Fine and Gray regression was used in a similar manner to assess the independent effect of EGF on aGvHD. 10 All statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA). All reported P-values are two-sided. Institutional Review Board (IRB) approval was obtained for this secondary analysis of all the clinical trial samples and data.
RESULTS
Patient (n = 247 individual patients in total, although not all 247 patients had available samples at each time point) and donor (n = 117) demographics with plasma samples analyzed were similar to the parent study (n = 304 HCT patients, not shown). donors compared with HCT recipients at the pre-HCT baseline visit (mean donor EGF of 76 pg/mL ± 5.9 versus 24.3 ± 3 pg/mL in HCT recipients, P o0.01, unpaired). Within HCT recipients, there were no differences in clinical characteristics (age, sex, year of HCT, aGvHD prophylaxis regimen (tacrolimus/sirolimus versus tacrolimus/methotrexate), conditioning regimen, underlying disease, CMV serostatus) between patients and EGF concentrations at baseline ( Table 1) .
The median time to onset of aGvHD was 28.5 days (interquartile range (IQR) 21-45.5 days), with 167 patients with grade 0-I aGvHD, 48 patients with grade II aGvHD, and 32 patients with grade III-IV aGvHD in this cohort. Plasma concentrations of EGF at pre-HCT baseline were associated with aGvHD outcomes. Two hundred and thirteen patients had baseline samples to analyze, and 91 (43%) of these had low (o 2.7 pg/mL) plasma EGF prior to the start of the conditioning regimen ( Figure 1 ). Patients with a low baseline EGF demonstrated a 2.9-fold increased risk of subsequently developing grade III-IV aGvHD (P = 0.01, Figure 2) . Approximately, sixty percent of patients who developed grade III-IV aGvHD overall had low EGF at the pre-HCT baseline, whereas the majority of patients who developed less severe aGvHD did not have low EGF prior to HCT (P = 0.03, Figure 3) . Although low pre-HCT baseline plasma EGF concentrations were associated with a significantly increased risk of subsequent development of grade III-IV aGVHD, they were not associated with overall survival at 1 year (P = 0.99).
Two hundred and twenty-two patients had day +28 samples to analyze, and overall 148 patients (67%) had low EGF at this time point. There was a weak correlation between baseline and day +28 EGF as a continuous variable (Spearman's rho = 0.27, Po 0.01). Only 22% of patients with baseline low EGF plasma concentrations (n = 20) had improvement in their EGF to ⩾ 2.7 pg/mL by day +28. Figure 3 . Percentage of patients with low epidermal growth factor (EGF) plasma concentrations (o2.7 pg/mL) by severity of acute graft versus host disease (aGvHD) and study visit.
Seventy-one percent of patients who developed grade III-IV aGvHD had low EGF at day +28, Figure 2 . Low day +28 plasma EGF o2.7 pg/mL was associated with a 15% worse overall survival at 1 year (73%, n = 149) compared with patients with higher plasma concentrations of EGF at this time point after after HCT (88%, n = 72, P = 0.02, Figure 4a) . A disproportionate number of deaths attributed to aGvHD were observed in the low EGF group at day +28 after HCT (9 versus 1 death due to aGvHD, Figure 4b ), although aGvHD was not the sole cause of poor survival. More deaths due to epithelial toxicities of HCT were observed in the low EGF at day +28 group (7 versus 5 deaths due to chronic GvHD, 5 versus 1 death due to liver failure/veno-occlusive disease (VOD) and 4 versus 1 death due to respiratory failure, Figure 3b ). In multivariate analysis for OS, a low plasma EGF at day +28 was associated with a 2.3-fold increased risk of death at 1 year (hazard ratio (HR) 2.3, 95% confidence interval (CI) 1.1-4.7, P = 0.02). Other factors considered were GvHD prophylaxis type, gender, year of transplant, age, diagnosis and CMV serostatus. Only low plasma EGF and age (50+ (HR 3.0, 95% CI 1.2-7.8, P = 0.02)) remained in our final model. Two hundred and six patients had day +100 samples to analyze, and 109 (53%) of these patients had low EGF at this time point. There were no significant differences in plasma EGF concentrations in patients with or without aGvHD who survived to day +100 (Figure 2 ), although a low EGF plasma concentration at day +100 was marginally associated with poorer overall survival (P = 0.06). Notably, 13 of 150 patients with a low day +28 EGF (9%) had died by day +100, whereas only 1 of 72 patients with higher day +28 EGF plasma concentrations died by day +100, making it possible that deaths prior to day +100 contributed to the lack of statistical significance at this time point.
DISCUSSION
Without important epithelial trophic factors, host tissues may have an impaired ability to repair and regenerate after myeloablative allogeneic HCT. Our results show that patients with hematologic malignancies have lower baseline EGF plasma concentrations compared to their healthy sibling donors. Furthermore, low pre-HCT EGF o2.7 pg/mL predisposed patients to the development of grade III-IV aGvHD. The myeloablative conditioning in BMT CTN 0402 (cyclophosphamide plus TBI) was associated with low EGF concentrations in most patients at day +28 after HCT. Importantly, patients with low EGF at day +28 had inferior overall survival due to toxicities of HCT, especially acute GvHD. These results further support the concept that tissue repair is compromised in patients experiencing toxicities of allogeneic HCT, including but not limited to severe aGvHD. Additional studies will be required to determine if a low pre-HCT EGF is a risk factor for grade III-IV aGvHD in the reduced intensity conditioning setting. A limitation of this study is that the soonest time point for post-HCT analysis is day +28, and in this cohort, half of the patients who developed aGvHD had already done so and were receiving therapy. Future studies should ideally assess the changes in EGF plasma concentrations from baseline relative to the onset of aGvHD at earlier timepoints (for example, as early as day +7 or day +14 after HCT but before the onset of aGvHD). An additional limitation of this study is that not all 247 patients had samples drawn at all three time points, which could have impacted the analysis. Finally, our findings have yet to be validated in an independent cohort.
In contrast to our previous study, we did not find differences in plasma EGF concentrations based upon the severity of aGvHD at day +100 after HCT. 11 However, many patients with low EGF plasma concentrations died prior to that time point in BMT CTN 0402. In addition, differences in patient populations (varying conditioning intensities in the previous study versus solely myeloablative in this cohort), sample source (serum in the previous study versus plasma in this cohort) or other factors may have contributed to differing results. Our findings may be specific to myeloablative, TBI-based conditioning regimens. Additionally, a larger cohort will help to confirm if EGF remains low, out to day +100 and beyond, in the wake of severe but non-fatal aGvHD.
We hypothesize that baseline EGF plasma concentrations observed in BMT CTN 0402 patients compared with their sibling donors may be low due to epithelial injury following cytotoxic chemotherapy. 12 Future studies will thus need to consider the potential interaction of chemotherapy-associated epithelial toxicities on circulating EGF plasma concentrations. Future studies should also include analysis of autologous HCT recipients as an additional control to determine the association of circulating EGF following recovery of mucosal toxicities of conditioning without the risk of aGvHD. These analyses will facilitate the development of rationally applied adjunctive therapies aimed at promoting tissue repair that may aid in the prevention and treatment of potentially fatal complications of allogeneic transplantation. EGF may be contributing to epithelial barrier integrity, mucin secretion and resistance to pathogen colonization and Clostridium difficile infection, [13] [14] [15] [16] [17] all of which would be beneficial for recovery from HCT. We are currently testing the utility of EGF supplementation in patients who develop high-risk or steroid-dependent/refractory aGvHD (Clinicaltrials.gov NCT02525029). 18 On the bassis of the results from the present study, allogeneic HCT recipients with low EGF early in the transplant process, from pre-HCT through day +28 after HCT, may be candidates for preemptive experimental approaches, such as supplemental EGF, to mitigate the increased risk of fatal aGvHD and toxic death after myeloablative conditioning. Clinical practice in HCT could be transformed by delivering regenerative therapies in a personalized manner to patients who demonstrate the need based upon low circulating EGF. 
